Fortitude Family Office’s Regenxbio RGNX Stock Holding History

Fortitude Family Office’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.54K	Buy	546 +488	+841%	+$4.05K	﹤0.01%	957
2026 Q1	$486	Buy	+58	New	+$609	﹤0.01%	1740

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Fortitude Family Office's RGNX Position: Q2 2026 in Review

Fortitude Family Office increased its Regenxbio (RGNX) stake by 841% in Q2 2026, buying an estimated $4.05K and bringing the position to 546 shares worth $6.54K. The position accounts for ﹤0.01% of the portfolio, ranked #957.

Fortitude Family Office first reported a position in RGNX in Q1 2026 and has held it in 2 quarters since. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

Fortitude Family Office held 546 shares of Regenxbio worth $6.54K as of Q2 2026.
Fortitude Family Office bought 488 Regenxbio shares in Q2 2026, an estimated $4.05K.
Regenxbio made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #957 holding.
Fortitude Family Office first reported a position in Regenxbio in Q1 2026 and has held it in 2 quarters since.
165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.